In partnership with
___________________________________________________________________
Todays top story:
Pharmaceutical Executive published a piece on prediction markets exposing a gap in pharma vendor contracts.
A biostatistician at a contract research organization reviews unblinded interim trial data months before a sponsor’s public readout.
That person is not a sponsor employee. That means they may not be covered by the sponsor’s trading policies.
And they can now buy event contracts on Kalshi pricing the probability of FDA approval for the exact drug they have non-public data on.
Some say this is the pharmaceutical version of the compliance gap the StarCompliance webinar flagged last week.
A CRO employee buying a Kalshi event contract on a clinical trial outcome falls completely outside those controls — even if the underlying information asymmetry is identical to insider trading on the stock.
The fix, according to experts quoted in the piece, starts with rewriting confidentiality language in vendor contracts to explicitly cover prediction market trading. Most pharma companies haven’t done that yet. The biostatistician, the lab technician, the regulatory affairs consultant — anyone with early access to trial or FDA data who isn’t a direct employee — is currently operating in a gap.
The House Oversight Committee has already expanded its insider trading investigation to five platforms. The CFTC probed former Representative Kinzinger for pardon-related trades. A pharma insider trading case on a clinical trial outcome would be the most financially significant case yet — and the compliance infrastructure to prevent it doesn’t exist.
🌙 Daily Prediction Market Moonshot Report
0.8 cents. YES. $1,300.
This wallet — third time we’ve seen this specific balance of power outcome bought — put $1,300 on YES at 0.8 cents yesterday afternoon.
Three weeks until the midterms. Three separate wallets have now bought this exact outcome. At 0.8 cents, $1,300 buys 162,500 YES shares. Payout: approximately $162,500.
3.0 cents. NO. $1,200. 2:03 AM this morning.
This wallet put $1,200 on NO — betting the US-Iran ceasefire breaks before tomorrow.
October 15 is today. At 3 cents NO, the market was still pricing a 3% chance of ceasefire breakdown with less than 24 hours left. This wallet is collecting the premium — or genuinely thinks it breaks today.
At 3 cents, $1,200 buys 40,000 NO shares. Payout: approximately $40,000.
🇷🇺 Putin out — another wallet, another night buy
This wallet put $1,100 on YES at 3.8 cents at 2:59 PM yesterday.
Seven separate wallets have now bought this market. The price has drifted from 2 cents to nearly 4 cents over two weeks. At 3.8 cents, $1,100 buys roughly 28,900 YES shares. Payout: approximately $28,900.
5.0 cents. YES. $1,200.
This wallet put $1,200 on the defending champions repeating. The Celtics won the 2026 title. At 5 cents, $1,200 buys 24,000 YES shares. Payout if Boston repeats: approximately $24,000.
___________________________________________________________________
The 10 Best AI Stocks to Own in 2026
AI is moving from experiment… to essential.
Every major industry is integrating it.
Every major company is investing in it.
By late 2025, AI was already an $800B market — growing at a pace that could push it well beyond $1 trillion in the years ahead.
Cloud infrastructure is scaling fast.
AI-enabled devices are multiplying.
Automation is becoming standard.
But here’s the real question…
When trillions flow into this transformation — which stocks stand to benefit most?
Our new report reveals 10 AI stocks positioned across the backbone of this shift — from the companies powering the infrastructure… to those embedding intelligence into everyday systems.
If you want exposure to one of the defining growth trends of this decade, start here.
___________________________________________________________________
DISCLAIMER:
The Content is not intended to provide, and does not constitute, financial, investment, trading, tax, legal, or any other form of professional advice. It is not a recommendation, suggestion, solicitation, or offer to buy, sell, trade, or hold any securities, event contracts, derivatives, cryptocurrencies, or other financial instruments on platforms such as Polymarket, Kalshi, or any other prediction market.
Prediction Market Edge believes the Content is reliable but makes no representations or warranties as to its accuracy, completeness, timeliness, or suitability for any purpose. The Content is subject to change without notice, and Prediction Market Edge assumes no duty or obligation to update it.
Trading in prediction markets involves significant risk of loss, including the potential loss of your entire investment. Past performance (including any highlighted “wins” or gains) is not indicative of future results. Markets are volatile, influenced by news, liquidity, resolution rules, and other factors, and individual results will vary. Subscribers and readers should conduct their own independent research, consider their financial situation, risk tolerance, and objectives, and consult qualified professionals before making any trading or investment decisions.
Prediction Market Edge is not responsible for any third-party information, market data, platform rules, or services referenced herein, including but not limited to Polymarket, Kalshi, or other exchanges. Use of the Content is at your own risk.
By subscribing to or accessing this Newsletter or related materials, you agree that Prediction Market Edge and its affiliates shall not be liable for any direct, indirect, incidental, consequential, or other damages arising from your use of the Content.
For important additional information, please review our full Terms of Service, Privacy Policy, and any Subscription Agreement (available on predictionmarketedge.com).